| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
In ZAZ and M14 melanoma cell lines, 48 hours of treatment with L-Buthionine-(S,R)-suLfoximine (BSO: 50 μM) led to a 95% reduction in GSH levels and a 60% reduction in GST enzyme activity. In both cell lines, there was a considerable decrease in the amounts of GST-π protein and mRNA [1]. By irreversibly blocking g-glutamylcysteine synthase, which synthesizes glutathione Essential enzyme for glycopeptide (GSH), L-buthionine-(S,R)-suLfoximine (BSO) produces cellular oxidative stress[2]. In cancer cells, L-Buthionine-(S,R)-suLfoximine (BSO) causes ferroptosis [3].
|
|---|---|
| ln Vivo |
BSO increases the frequency of DNA deletions in developing mice. BSO treatment decreased GSH levels in mouse fetuses by 55% and 70% at 2 mM and 20 mM BSO dosages, respectively, in comparison to untreated mice. In line with BSO's ability to inhibit the g-GCS enzyme, which is necessary for GSH synthesis, co-treatment with 2 mM BSO and 20 mM NAC reduced GSH to a level comparable to that of 2 mM BSO. Following BSO therapy, cysteine levels fall, similar to GSH [2].
|
| Animal Protocol |
Animal/Disease Models: C57BL/6J pun/pun mice[2].
Doses: 2mM L-Buthionine-(S,R)-sulfoximine (BSO), 20mM BSO, 2mMBSO and 20mM NAC, 20mM NAC or unsupplemented water for 18 days from 0.5 to 18.5 dpc The pH of supplemented water is as follows: 6.88, 20mM BSO; 3.37, 2mMBSO; 2.65, 2mMBSO plus 20mM NAC; and 2.58, 20mM NAC. The pH of regular water used in our facility is ~4. Route of Administration: Drinking water. Experimental Results: The average number of eye-spots (mean±SEM) is 5.36±0.29 (n=46), 7.79±0.45 (n=34) and 8.78± 0.61 (n=32) in untreated controls, 2 mM L-Buthionine-(S,R)-sulfoximine (BSO) and 20 mM BSO treated mice, respectively. The 2 mM BSO treatment results in ~30% more eye-spots, and the 20 mM treatment results in 40% more eye-spots compared with untreated mice. |
| References |
|
| Molecular Formula |
C8H19CLN2O3S
|
|---|---|
| Related CAS # |
DL-Buthionine-(S,R)-sulfoximine;5072-26-4;L-Buthionine-(S,R)-sulfoximine;83730-53-4;DL-Buthionine-(S,R)-sulfoximine hydrochloride
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~250 mg/mL (~966.11 mM)
H2O :~70 mg/mL (~270.51 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
